Influenza APhase 3NCT03381196
A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications
A Phase 3 study testing Pimodivir 600 mg and SOC Treatment in people with Influenza A, run by Janssen Research & Development, LLC at 427 sites in 38 countries.
Trial summary
The purpose of this study is to evaluate the clinical and virologic benefit of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment. Read more about this study
- Who is it for?
- Ages 13 to 85 years
- Conditions the study is for
- Influenza A
- What is being tested?
- Pimodivir 600 mg and SOC Treatment
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 553 participants
- Where
- 427 sitesin 38 countries
- Study dates
- 21 Jan 2018to 24 Aug 2020
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 13 to 85 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Present to the clinic with symptoms suggestive of a diagnosis of acute influenza and have at least 1 respiratory symptom and at least 1 systemic symptom, both scored as at least "moderate" if the symptom did not pre-exist before influenza onset, or scored worse than usual if the symptom pre-existed as determined by subject's ratings on Module 1 of the Flu-iiQ and the Pre-existing Symptom Questionnaire in the ePRO device. Symptoms must include the following by category: a) Respiratory symptoms: cough, sore throat, nasal congestion b) Systemic symptoms: headache, body aches or pain, feverishness, fatigue
- Tested positive for influenza A infection after the onset of symptoms, using a rapid influenza diagnostic test (RIDT) or, if available, a polymerase chain reaction (PCR)-based or other rapid molecular diagnostic assay
- Not be in need of hospitalized medical care at screening. Emergency room or hospital observation status for an anticipated duration of less than (<)24 hours is not considered hospitalization as long as a determination of the need for hospitalization has not been made
- Enrollment and initiation of study drug treatment less than or equal to (<=)72 hours after onset of influenza symptoms
- Participants 13 to 65 years of age, inclusive must also have at least 1 of the following: a) Cardiovascular or cerebrovascular disease (including congenital heart disease, chronic heart failure, coronary artery disease, or stroke; excluding isolated hypertension); b) Chronic lung disease (for example, asthma, chronic obstructive lung disease [COPD] or cystic fibrosis); c) Weakened immune system due to disease or medication (for example, participants with human immunodeficiency virus [HIV], cancer, or chronic liver or kidney disease [presence of kidney damage for >3 months, defined by structural or functional abnormalities of the kidney, with or without decreased GFR manifested by: pathological abnormalities; OR markers of kidney damage, including abnormalities in the composition of the blood or urine or abnormalities in imaging tests], or participants taking chronic systemic steroids)
Who cannot join
- Received more than (>)1 dose of influenza antiviral medication (for example, oseltamivir [OST] or zanamivir), or any dose of ribavirin within 2 weeks, prior to first study drug intake, or received intravenous (IV) peramivir >1 day prior to screening
- Unstable angina pectoris or myocardial infarction within 30 days prior to screening (inclusive)
- Presence of clinically significant heart arrhythmias, uncontrolled, unstable atrial arrhythmia, or sustained ventricular arrhythmia, or risk factors for Torsade de Pointes syndrome
- Known severe hepatic impairment (Child Pugh C cirrhosis) or chronic hepatitis C infection undergoing hepatitis C antiviral therapy
- Severely immunocompromised in the opinion of the investigator (for example, known cluster of differentiation 4 plus [CD4+] count <200 cells per cubic millimeter [cells/mm^3], absolute neutrophil count <750/mm^3, first course of chemotherapy completed within 2 weeks prior to screening, history of stem cell transplant within 1 year prior to screening, history of a lung transplant)
Trial locations and contacts
427 sites in 38 countries.
427 sites in 38 countries
United States140 sites
HIRG, LLC dba Health Innovation Research Group
Arlington, Texas, 76014
Millennium Clinical Trials LLC
Arlington, Virginia, 22203
ACRC Trials
Austin, Texas, 78735
University Of Maryland Medical Center
Baltimore, Maryland, 21201
Johns Hopkins University School of Medicine
Baltimore, Maryland, 21218
University of Alabama at Birmingham
Birmingham, Alabama, 35233
Alabama Clinical Therapeutics, LLC
Birmingham, Alabama, 35235
Cahaba Research Inc
Birmingham, Alabama, 35242
Massachusetts General Hospital
Boston, Massachusetts, 02114
Val Hansen
Bountiful, Utah, 84010
Craig A. Spiegel, MD
Bridgeton, Missouri, 63044
PMG Research of Bristol
Bristol, Tennessee, 37620
Investigators Research Group, LLC
Brownsburg, Indiana, 46112
Mercury Street Medical Group, PLLC
Butte, Montana, 59701
SC Clinical Research Inc.
California City, California, 92844
Family Medicine Associates of Texas
Carrollton, Texas, 75010
Accellacare Research of Cary
Cary, North Carolina, 27518
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611
Onsite Clinical Solutions
Clemmons, North Carolina, 27012
Ericksen Research and Development
Clinton, Utah, 84015
Lynn Institute
Colorado Springs, Colorado, 80920
University of Texas Southwestern Medical Center
Dallas, Texas, 75390
Dayton Clinical Research
Dayton, Ohio, 45406
WR-Global Medical Research, LLC
DeSoto, Texas, 75115
Wayne State Univ School of Medicine
Detroit, Michigan, 48201
Wayne State University
Detroit, Michigan, 97205
Moonshine Research Center, Inc
Doral, Florida, 33166
J. Lewis research Inc./ Foothill Family Clinic South
Draper, Utah, 84020
Centennial Medical Group
Elkridge, Maryland, 21075
Medisphere Medical Research Center, Llc
Evansville, Indiana, 47714
Carolina Institute for Clinical Research
Fayetteville, North Carolina, 28304
Research Center of Fresno Inc
Fresno, California, 93702
Spectrum Medical Research
Gaffney, South Carolina, 29341
University Of Texas Medical Branch At Galveston
Galveston, Texas, 77555
clinical research of Gastonia
Gastonia, North Carolina, 28054
San Gabriel Clinical Research, LLC
Georgetown, Texas, 78626
Allied Clinical Research
Gold River, California, 95670
DeGarmo Institute of Medical Research
Greer, South Carolina, 29651
Innovative Clinical Research Inc
Harbor City, California, 90710
Best Quality Research Inc
Hialeah, Florida, 33016
Floridian Clinical Research LLC
Hialeah, Florida, 33016
The community Research of South Florida
Hialeah, Florida, 33016
Hickory Research Center.
Hickory, North Carolina, 28601
Buckeye Health and Research, LLC
Hilliard, Ohio, 43027
Encore Medical Research, LLC
Hollywood, Florida, 46112
Homestead Associates in Research Inc
Homestead, Florida, 33032
BI Research Center
Houston, Texas, 77043
West Houston Clinical Research Service
Houston, Texas, 77055
Northwest Med Care,P.A.
Houston, Texas, 77070
Southwest Clinical Trials
Houston, Texas, 77074
Dairy Ashford Family Practice
Houston, Texas, 77077
JM Research.PLLC
Houston, Texas, 77083
PCP for Life
Houston, Texas, 77093-6731
Hutchinson Clinic
Hutchinson, Kansas, 67502
Snake River Research, PLLC
Idaho Falls, Idaho, 83404
Care Partners Clinical Research
Jacksonville, Florida, 32218
PMG Research of Knoxville
Jefferson City, Tennessee, 37760
PMG Research of Knoxville
Knoxville, Tennessee, 37912
Barrett Clinic P.C.
La Vista, Nebraska, 68128
Premier Medical Group
Lady Lake, Florida, 32159
Om Research LLC
Lancaster, California, 93534
Lancaster General Hospital
Lancaster, Pennsylvania, 29720
Detweiler Family Medicine and Associates
Lansdale, Pennsylvania, 19446
Next Phase Research Alliance
Las Vegas, Nevada, 89119
The Research Group of Lexington, LLC
Lexington, Kentucky, 40503
Ark Clinical Research
Long Beach, California, 90806
Miller Children's Hospital
Long Beach, California, 90806
Downtown LA Research Center, Inc
Los Angeles, California, 90017
California Allergy & Asthma Medical Group Inc.
Los Angeles, California, 90025
Adam D. Karns, MD
Los Angeles, California, 90036
SMS Clinical Research LLC
Mesquite, Texas, 75149
Clinical Trials Management, LLC
Metairie, Louisiana, 70006
Medpharmics, LLC
Metairie, Louisiana, 70006
Sima Research Clinic
Miami, Florida, 33125
Universal Clinical Research Associates
Miami, Florida, 33134
South Florida Research Center Inc.
Miami, Florida, 33135
A Plus Research
Miami, Florida, 33144
Nuren Medical & Research Center
Miami, Florida, 33144
Coral Research Clinic Corp
Miami, Florida, 33175
New Horizon Research Center
Miami, Florida, 33175
Vista Health Research, LLC
Miami, Florida, 33176
Crystal Biomedical Research
Miami Lakes, Florida, 33014
Montana Medical Research
Missoula, Montana, 59808
Monroe Biomedical Research
Monroe, North Carolina, 28112
Burke Primary Care
Morganton, North Carolina, 28655
PMG Research of Charleston, LLC
Mt. Pleasant, South Carolina, 29464
Saltzer Medical Group
Nampa, Idaho, 83686
Saint Michaels Medical Center
Newark, New Jersey, 07102
Complete Family Care
Northglenn, Colorado, 80234
Lucita M. Cruz Md Inc
Norwalk, California, 90650
Advanced Research Institute
Ogden, Utah, 84405
Nebraska Medical Center
Omaha, Nebraska, 68198
Combined Research Orlando
Orlando, Florida, 32803
Clinical NeuroScience Solutions Inc
Orlando, Florida, 32806
Omega Research Consultants
Orlando, Florida, 32810
Asclepes Research
Panorama City, California, 91402
Center for Clinical Trials LLC
Paramount, California, 90723
Pines Care Research Center Inc
Pembroke Pines, Florida, 33026
South Broward Research, LLC
Pembroke Pines, Florida, 33027
Albert Einstein Healthcare Network
Philadelphia, Pennsylvania, 19141
Preferred Primary Care Physicians Research
Pittsburgh, Pennsylvania, 15236
Village Health Partners
Plano, Texas, 75024
Health Concepts
Rapid City, South Dakota, 57702
Granger Medical Clinic-Riverton
Riverton, Utah, 84065
PMG Research of Rocky Mount, LLC
Rocky Mount, North Carolina, 27804
William Beaumont Hospital
Royal Oak, Michigan, 48073
Benchmark Research
Sacramento, California, 95684
J. Lewis research Inc./ Foothill Family Care
Salt Lake City, Utah, 84109
J. Lewis research Inc./ Foothill Family Clinic South
Salt Lake City, Utah, 84121
J. Lewis Research Inc/ FirstMed East
Salt Lake City, Utah, 84121
Tekton Research Inc.
San Antonio, Texas, 78240
DM Clinical Research
San Antonio, Texas, 78249
Medical Associates Research Group, Inc.
San Diego, California, 92123
San Diego Sports Medicine & Family Health Center
San Diego, California, 92129
West Coast Clinical Research, LLC
San Ramon, California, 94582
Destin Pulmonary Critical Care, PLLS.
Santa Rosa Beach, Florida, 32459
Scottsboro Quick Care Clinic
Scottsboro, Alabama, 35768
North Star Clinical Research, LLC
Shreveport, Louisiana, 71104
Frontier Clinical Research
Smithfield, Pennsylvania, 15478
J. Lewis Research Inc./Jordan River Family Medicine
South Jordan, Utah, 84095
Fusion Clinical Research of Spartanburg
Spartanburg, South Carolina, 29301
Stanford University
Stanford, California, 94305-5640
Tri County Research, Inc.
Sterling Heights, Michigan, 48310-3503
Vita Health and Medical center
Tamarac, Florida, 33319
Renovatio Clinical
The Woodlands, Texas, 77380
William Beaumont Hospital
Troy, Michigan, 48085
Arcturus Healthcare PLC
Troy, Michigan, 48098
Preferred Primary Care Physicians Research
Uniontown, Pennsylvania, 15401
AAPRI Clinical Research Institute
Warwick, Rhode Island, 02886
Emerson Clinical Research Institute
Washington D.C., District of Columbia, 20011
Chase Medical Research, LLC
Waterbury, Connecticut, 06708
ClinPoint Trials
Waxahachie, Texas, 75165
Asclepes Research
Weeki Wachee, Florida, 34607
Axcess Medical Research, LLC
Wellington, Florida, 33414
Invocare Clinical Research Center
West Columbia, South Carolina, 29169
Paradigm Clinical Research Centers, Inc.
Wheat Ridge, Colorado, 80033
PMG Research of Wilmington, LLC
Wilmington, North Carolina, 28401
Clinical Trials of America
Winston-Salem, North Carolina, 27103
Southeastern Research Center LLC
Winston-Salem, North Carolina, 27103
Cozy Research, Llc
Zephyrhills, Florida, 33541
South Africa34 sites
Cardiology Clinical Research
Alberton, 1449
Josha Research
Bloemfontein, 9301
Dr Dindar & Partner
Breyten, 2330
Endocare Research
Cape Town, 7646
Uhuru Clinical Trial Centre
Cape Town, 7764
Dr EL Janari Private Practice
Cape Town, 7945
Precise Clinical Solutions
Chatsworth, 4092
Abdullah, IA
Durban, 4001
Sebastian, Peter
Durban, 4001
Pillai, P
Durban, 4068
Govind, U
Durban, 4096
Jeevren Reddy, MD
Durban, 4450
Global Clinical Research SA
Durban North, 4051
CRISMO Bertha Gxowa Research Centre
Johannesburg, 1401
Peermed Clinical Trial Centre
Kempton Park, 1619
DJW Research
Krugersdorp, 1739
Aliwal Shoal Medical Centre
KwaZulu-Natal, 4170
Dr A Jacovides Clinical Trials Inc.
Midrand, 1685
Dr AA Mahomed Medical Centre
Moloto South, 1022
Newtown Clinical Research
Newtown, 2113
Pillay, SR
Ottawa, 4339
Smartmed Research Centre
Port Elizabeth, 6020
Emmed Research
Pretoria, 0084
Botho ke Bontle Health Services
Pretoria, 0101
Into Research
Pretoria, 0181
Jongaie Research
Pretoria, 0183
Queenswood Clinical Trial Centre
Pretoria, 0186
Engelbrecht, I
Pretoria, 157
Johese Clinical Research
Pretoria, 1692
Wits Clinical Research
Soweto, 2013
Limpopo Clinical Research Initiative
Thabazimbi, 380
Clinteam Vaal Clinical Trial Centre
Van Der Bijl, 1911
Welkom Clinical Trial Centre
Welkom, 9460
Moriana Clinical Research
Winnie Mandela, 9400
Hungary15 sites
DRC Gyogyszervizsgalo Kozpont Kft
Balatonfüred, 8230
Clinexpert Kft
Budapest, 1033
Obudai Egeszsegugyi Centrum Kft
Budapest, 1036
Eszak Kozep budai Centrum Uj Szent Janos Korhaz es Szakrendelo Budai Csaladkozpontu
Budapest, 1122
Strázsahegy Medicina Bt
Budapest, 1171
Pestszentimrei Gyermekrendelő
Budapest, 1188
Bugat Pal Korhaz
Gyöngyös, 3200
Futurenest Klinikai Kutato Kft.
Miskolc, 3527
Mohacsi Korhaz
Mohács, 7700
Borbanya Praxis Eu. Kft.
Nyíregyháza, 4400
Medifarma-98 Kft.
Nyíregyháza, 4400
DRC Szentendre
Szentendre, 2000
Tudogyogyintezet Torokbalint
Törökbálint, 2045
DRC Zamardi
Zamárdi, 8621
DRC Zirc
Zirc, 8420
Argentina14 sites
Hospital Interzonal General de Agudos Dr. Jose Penna
Bahía Blanca, B8001DDU
CEMIC Saavedra
Ciudad de Buenos Aires, 1431
Hospital Nuestra Señora de la Misericordia
Córdoba, 5000
Hospital Rawson
Córdoba, 5000
Hospital San Roque
Córdoba, 5000
Sanatorio Allende
Córdoba, X5000JHQ
Hospital Cordoba
Córdoba, X5004CDT
Hospital Privado Centro Medico de Cordoba
Córdoba, X5016KEH
Sanatorio Juan XXIII
General Roca, 8332
Sanatorio del Oeste Ituzaingo
Ituzaingo, 1714
Instituto Medico Platense
La Plata, B1900AVG
Hospital Italiano de La Plata
La Plata Lpl Lpl, 1900
Sanatorio Britanico S.A.
Rosario, 2000
Instituto Del Buen Aire
Santa Fe, 3000
India14 sites
Rajiv Gandhi Institute of Medical Sciences
Balaga, 532001
M S Ramaiah Memorial Hospital
Bangalore, 560054
S. R. Kalla Memorial General Hospital
Jaipur, 302001
Midland Healthcare & Research Center
Lucknow, 226006
Kasturba Medical College Hospital
Manipal, 576104
Suretech Hospital and Research Centre Limited
Nagpur, 400012
Siddhi Hospital
Nashik, 422007
BLK Super Specialty Hospital
New Delhi, 110005
Sir Ganga Ram Hospital
New Delhi, 110060
Sahyadri Speciality Hospital
Pune, 411004
Lifepoint Multispecialty Hospital
Pune, 411023
Shree Giriraj Multispeciality Hospital
Rajkot, 360005
Unique Hospital
Surat, 395002
BAPS Pramukhswami Hospital
Surat, 395009
Brazil13 sites
Santa Casa de Misericordia de Belo Horizonte
Belo Horizonte, 30150-221
Infection Control Ltda
Brasil, 30110-063
Hrpc Ulbratech - Ulbra
Canoas, 92425
Centro de Estudos Clínicos do Interior Paulista - CECIP
Jaú, 17201-150
CMIP - Centro Mineiro de Pesquisa Ltda
Juiz de Fora, 36010 570
Associacao Hospitalar Beneficente Sao Vicente de Paulo - Hospital Sao Vicente de Paulo
Passo Fundo, 99010-080
Hospital das Clinicas de Porto Alegre
Porto Alegre, 90035-903
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
Porto Alegre, 90610-000
CCBR Brasil Centro de Pesquisas e Análises Clínicas Ltda.
Rio de Janeiro, 22271-100
Pesquisare Saude
Santo André, 09080-110
CEMEC - Centro Multidisciplinar de Estudos Clínicos
São Bernardo do Campo, 09780-000
Irmandade Santa Casa de Misericordia de Sao Paulo
São Paulo, 01221-020
Fundacao Jose Luiz Egydio Setubal
São Paulo, 01227-200
South Korea13 sites
Chungbuk National University Hospital
Cheongju-si, 28644
Yonsei University Wonju Severance Christian Hospital
Gangwon-do, 220-701
Korea University Ansan Hospital
Gyeonggi-do, 15355
Hallym University Dongtan Sacred Heart Hospital
Hwaseong-si, 18450
Inha University Hospital
Incheon, 22322
The Catholic University of Korea, Incheon St. Mary's Hospital
Incheon, 403-720
Dong-A University Hospital
Pusan, 602-715
Korea University Anam Hospital
Seoul, 02841
Konkuk University Medical Center
Seoul, 05030
Asan Medical Center
Seoul, 05505
Hallym University Kangnam Sacred Heart Hospital
Seoul, 07441
Korea University Guro Hospital
Seoul, 8308
The Catholic university of Korea ST Vincent Hospital
Suwon, 16247
Latvia11 sites
Liga Kozlovska family doctor practice
Balvi, LV4501
OLVI Medical Centre
Daugavpils, LV-5401
Baiba Bake GP practice
Jelgava, LV3001
Ruta Eglite's Private Practice
Kuldīga, LV-3301
Inese Cebere GP practice
Liepāja, LV-3401
S. Boreiko Doctor's Practice
Ogre, LV-5001
Children's Clinical University Hospital
Riga, LV-1004
Clinic of GP A.Lasmanis 'ALMA'
Riga, LV-1010
Health Centre 4
Riga, LV-1012
Inese Petrova General Practitioner Practice
Tukums, LV-3101
Medical Practice BINI
Ventspils, LV3601
Bulgaria10 sites
SHATPPD - Ruse Ltd.
Rousse, 7002
MHAT Knyaginya Klementina
Sofia, 1233
MHAT 'Lyulin' EAD
Sofia, 1336
Acibadem City Clinic Tokuda Hospital
Sofia, 1407
DCC II- Sofia EOOD
Sofia, 1606
Medical Center 'N. I. Pirogov', EOOD
Sofia, 1606
Medical Center Excelsior OOD
Sofia, 1606
Military Medical Academy - Sofia
Sofia, 1606
MHAT Dr Stefan Cherkezov
Veliko Tarnovo, 5000
MC 'Sv. Ivan Rilski', OOD
Vidin, 3700
Russia10 sites
Institute Of Epidimiology And Microbiology
Kazan', 420015
Limited Liability company 'MSMC' Euromed
Omsk, 644024
LLC Outpatient department of Private Security Guards and Detectives
Saint Petersburg, 192007
LLC Institute of Medical Examinations
Saint Petersburg, 196084
LLC Kurator
Saint Petersburg, 196240
FSBI 'Scientific and Research Institute of Flu' of the MoH of the RF
Saint Petersburg, 197376
LLC 'ArsVite'
Stavropol, 355020
Siberian State Medical University
Tomsk, 634061
Clinical Hospital #3
Yaroslavl, 150007
SBEI HPE 'Yaroslavl State Medical University' of the MoH of the RF
Yaroslavl, 150010
Spain10 sites
Hosp. Gral. Univ. de Elche
Elche, 03203
Hosp. Univ. San Cecilio
Granada, 18012
Hosp. Univ. Virgen de Las Nieves
Granada, 18014
Hosp. Univ. de La Princesa
Madrid, 28006
Hosp. Clinico San Carlos
Madrid, 28040
Hosp. Univ. 12 de Octubre
Madrid, 28041
Hosp. Univ. La Paz
Madrid, 28046
Hosp. Univ. Hm Monteprincipe
Madrid, 28660
Hosp. Clinico Univ. de Santiago
Santiago de Compostela, 15706
Hosp. Alvaro Cunqueiro
Vigo, 36213
Belgium9 sites
CHU Saint-Pierre
Brussels, 1000
Hopital Erasme
Brussels, 1070
Institut Jules Bordet
Brussels, 1070
De Meulemeester, Marc
Gozée, 6534
Jaak Mortelmans
Ham, 3945
Quartier du Furgy 4
Herbeumont, 6887
Research Link
Linkebeek, 1630
BVBA Dr. Luc Capiau
Massemen, 9230
Testumed
Tessenderlo, 3980
Lithuania9 sites
Auki Sveikas
Kaunas, 44175
Silainiai Family Health Center, JSC
Kaunas, 48259
Saules Seimos Medicinos Centras, JSC
Kaunas, 49449
Hospital of Lithuanian University of Health Sciences Kaunas Clinics
Kaunas, LT-50009
Siauliai Republican Hospital, Public Institution
Šiauliai, 76231
Inlita, JSC, Lazdynai KTC clinical trial site
Vilnius, 4130
Central Outpatient Clinic
Vilnius, LT-01117
Inlita, JSC
Vilnius, LT-08406
Vilnius University Hospital Santaros Klinikos, Public Institution
Vilnius, LT-08661
Mexico9 sites
Hospital Cardiologica Aguascalientes
Aguascalientes, 20230
Centro para el Desarrollo de la Medicina y de Asistencia Médica Especializada S.C.
Culiacán, 80230
Centro de Investigacion Medico Biologica y Terapia Avanzada CIMBYTA
Guadalajara, 44130
Hospital Civil de Guadalajara Fray Antonio Alcalde
Guadalajara, 44280
Hospital Civil de Guadalajara Dr. Juan I. Menchaca
Guadalajara, 44340
Centro Medico Jojutla
Jojutla, 62900
Hospital Infantil de Mexico Federico Gomez
Mexico City, 6720
Hospital Universitario de Nuevo Leon 'Dr Jose Eleuterio Gonzalez'
Monterrey, 64460
Clinical Trials Mexico S.A. de C.V.
Pahucha, 42070
France8 sites
Centre Hospitalier d'Agen
Agen, 47923
Centre Hospitalier Intercommunal de Créteil
Créteil, 94010
Centre Hospitalier Départemental
La Roche S/ Yon Cedex 9, 85925
CHU de Grenoble Hopital Albert Michallon
La Tronche, 38043
CHU Nantes - Hotel Dieu
Nantes, 44093
CHU De Nice Hopital De l'Archet
Nice, 06202
Hôpital Bichat - Claude Bernard
Paris, 75018
Hopital Cochin
Paris, 75679 Cedex 14
Canada7 sites
Aggarwal and associates Ltd
Brampton, Ontario, L6T 0G1
Commonwealth Medical Clinic
Mount Pearl, Newfoundland and Labrador, A1N 1W7
SKDS Research Inc.
Newmarket, Ontario, L3Y 5G8
Recherche Clinique Sigma Inc.
Québec, Quebec, G1G 4A2
The Bailey Clinic
Red Deer, Alberta, T4N 6V7
Bluewater Clinical Research Group Inc.
Sarnia, Ontario, N7T 4X3
Dr. Anil K Gupta Medicine Professional Corporation
Toronto, Ontario, M9V 4B4
Germany7 sites
Universitaetsklinikum Koelnt
Cologne, 50937
MECS GmbH Cottbus
Cottbus, 03050
Jung, Thomas
Deggingen, 73326
Universitaetsklinik Erlangen
Erlangen, 91054
Universitaetsklinikum Giessen und Marburg GmbH
Giessen, 35392
Gemeinschaftspraxis Dr. Klein/ Minnich
Künzing, 94550
Gemeinschaftspraxis Dr. Taeschner / Dr. Bonigut
Leipzig, 04249
Turkey (Türkiye)7 sites
Hacettepe University Medical Faculty
Ankara, 06100
Adnan Menderes University
Aydin, 09100
Uludag University Medical Faculty
Bursa, 16059
Diyarbakir University Medical Faculty
Diyarbakır, 21080
Kocaeli University Medical Faculty
Kocaeli, 41380
Hacettepe University Medical Faculty
Samanpazarı, 06100
Karadeniz Teknik University Medical Faculty
Trabzon, 61080
Czechia6 sites
ADMED s.r.o.
České Budějovice, 37006
Sanare, s.r.o.
České Budějovice, 37006
Nemocnice Kyjov, p.o.
Kyjov, 697 01
Praktik Pb s.r.o
Příbram, 26101
SARKAMED s.r.o.
Slaný, 274 01
Prakticky lekar
Sokolov, 356 01
Estonia6 sites
Private GP Ilme Last
Paide, 72712
Vee Family Doctor's Center OY
Paide, 72713
OU Innomedica
Tallinn, 10117
Merelahe Family Doctors Center
Tallinn, 10617
Pirita Family Doctors Centre
Tallinn, 11911
Family Doctors Pullerits & Gavronski
Tartu, 51014
Israel6 sites
Barzilai Medical Center
Ashkelon, 78278
Bnai Zion Medical Center
Haifa, 31048
Galilee Medical Center
Nahariya, 22100
Chaim Sheba Medical Center
Ramat Gan, 52621
Kaplan Medical Center
Rehovot, 7610001
Ziv Medical Center
Safed, 13100
Poland6 sites
Malopolskie Centrum Alergologii
Krakow, 31-624
Centrum Medyczne w Lancucie Sp.z o.o.
Łańcut, 37-100
ETG Lodz
Lodz, 90 302
Powiatowe Centrum Medyczne w Wolowie Sp z o o
Specjalistyczna W Brzegu Dolnym, 58 120
Gabinet Lekarski Pediatryczno-Alergologiczny
Sucha Beskidzka, 34-200
NZOZ Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska
Wroclaw, 51 162
China5 sites
Chinese PLA General Hospital
Beijing, 100853
Fuzhou General Hospital of Nanjing Military Command
Fuzhou, 350000
The First Affiliated Hospital of NanChang University
Nanchang, 330006
Wuxi People s Hospital
Wuxi, 214000
Henan Provincial Peoples Hospital
Zhengzhou
Peru5 sites
Complejo Hospitalario San Pablo
Lima, 33
Clínica Sanna San Borja
Lima, 41
Clínica Internacional
Lima, Lima 01
Hospital Maria Auxiliadora
Lima, LIMA 29
Clinica Peruano Americana S.A
Trujillo, 13007
Taiwan5 sites
Taipei Medical University Shuang-Ho Hospital
New Taipei City, 23561
Kuang Tien General Hospital, Shalu
Taichung
National Taiwan University Hospital
Taipei, 10002
Taipei Medical University
Taipei, 110
Taipei Medical University-Wan Fang Hospital
Taipei, 116
Thailand5 sites
The Hospital for Tropical Diseases
Bangkok, 10400
Siriraj Hospital
Bangkok, 10700
Srinagarind Hospital
Muang, 40002
Bamrasnaradura Infectious Disease Institute
Nonthaburi, 11000
Bumrungrad Hospital
Wattana, 10110
Ukraine5 sites
Med San Unit OJSC Kharkiv S.OrdzhonikidzeTractor Plant Dept of Ther KMA PGE
Kharkiv, 61106
Kyiv Oleksandrivska Clinical Hospital
Kyiv, 1601
Odesa City Municipal Institution Polyclinic #20
Odesa, 65114
Poltava Regional Clinical Hospital HSEI of Ukraine Ukrainian Medical Stomatological Academy
Poltava, 36000
CCH #1 Vinnytsia M.I. Pyrogov NMU Ch of Propaedeutics of IM
Vinnytsia, 21021
United Kingdom5 sites
Swan Lane Medical Centre
Bolton, BL 6 6QT
Bodey Medical Centre
Manchester, M14 6WP
Barlow Medical Centre
Manchester, M20 2RN
West Timperley Medical Centre
Manchester, WA14 5PF
Northenden Group Practice
Northenden, M22 4DH
Italy4 sites
ASST Grande Ospedale Metropolitano Niguarda
Milan, 20162
AOU Policlinico di Modena
Modena, 41124
Azienda Socio Sanitaria Territoriale di Monza Presidio San Gerardo
Monza, 20052
Azienda Ospedaliera Universitaria Integrata Verona
Verona, 37126
Malaysia4 sites
Klinik Kesihatan Cheras Baru
Cheras Baru, 56100
Klinik Kesihatan Kuang
Kuang, 48050
Hospital Miri
Miri, 98000
Hospital Taiping
Taiping, 34000
New Zealand4 sites
Southern Clinical Trials Ltd
Auckland, 1050
Culloden Research Ltd
Papamoa, 3118
Lakeland Family Medical Services Ltd
Rotorua, 3010
Wellington Hospital
Wellington, 6021
Slovakia4 sites
Alersa, S.R.O.
Košice, 04022
Nemocnica s poliklinikou S. Kukuru Michalovce, a.s.
Michalovce, 07101
Plucna ambulancia Hrebenar, s.r.o.
Spišská Nová Ves, 05201
Nemocnica arm. generala L. Svobodu Svidnik, a.s.,
Svidník, 08901
Sweden4 sites
Department for Heart Failure and Valvular Disease
Malmö, 205 02
City Diabetes
Stockholm, 11157
Norrlands Universitetssjukhus
Umeå, 901 87
Akademiska Sjukhuset
Uppsala, 75185
Chile3 sites
Hospital El Pino
San Bernardo, 13560
Centro de Investigacion del Maule
Talca, 00000
Hospital de Niños y Cunas
Viña
Netherlands3 sites
Huisartsenpraktijk Zijtregtop
Rotterdam, 3037 AN
Huisartsenpraktijk Mangal
The Hague, 2565 KV
Huisartsenpraktijk Top
Zwijndrecht, 3334 SB
Vietnam3 sites
Bach Mai Hospital
Hanoi, 100000
National Hospital for Tropical Diseases
Hanoi, 100000
Nguyen Tri Phuong Hospital
Ho Chi Minh City
Australia2 sites
Northside Health
Coffs Harbour, 2450
Mater Hospital Brisbane
South Brisbane, 4101
Austria2 sites
AKH - Medizinische Universitat Wien
Vienna, 1090
SMZ Süd - Kaiser Franz Josef Spital Wien
Vienna, 1100
About this study
Official title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized Subjects With Influenza A Infection Who Are at Risk of Developing Complications
The purpose of this study is to evaluate the clinical and virologic benefit of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment.
Read the detailed description
This double-blind (neither researchers nor participants know what treatment participant is receiving) study will evaluate efficacy/safety of pimodivir in combination with SOC treatment versus placebo in combination with SOC treatment in adolescent (13 to 17 years), adult (18 to 65 years), and elderly (greater than [>] 65 but less than or equal to [<=] 85 years) non-hospitalized participants with influenza A infection who are at risk of developing complications. The study will be conducted in 3 phases: screening phase, double-blind treatment period (5 days), a post treatment follow-up period (23 days). Study evaluations include efficacy, clinical and virological outcomes, pharmacokinetics (PK), PK/pharmacodynamics, biomarkers, safety and tolerability. The duration of participation in the study for each participant is 28 days.
- Conditions
- Influenza A
- Being tested
- Pimodivir 600 mg, Placebo, SOC Treatment
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pimodivir 600 mgDrug
Also called JNJ-63623872
Participants will receive pimodivir 600 mg, orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6).
PlaceboDrug
Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until the morning of Day 6).
SOC TreatmentOther
Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon).
| Study group | Role | What they receive |
|---|---|---|
| Treatment Arm 1 (pimodivir + SOC treatment) | Experimental | Participants will receive pimodivir 600 milligram (mg), orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6) along with Standard-of-Care (SOC) treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected adverse event (AE). Receives: Drug: Pimodivir 600 mg; Other: SOC Treatment |
| Treatment Arm 2 (placebo + SOC treatment) | Placebo comparator | Participants will receive placebo matching to pimodivir orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until the morning of Day 6) along with SOC treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE. Receives: Drug: Placebo; Other: SOC Treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to Resolution of 7 Primary Influenza-related Symptoms as Assessed by the Patient-Reported Outcome (PRO) Measure Flu-Intensity and Impact Questionnaire (Flu-iiQ)
The Flu-iiQ is a PRO that measures influenza symptom intensity (none, mild, moderate, or severe) on a 4 point Likert response rating scale ranging from 0 to 3, where "0" represents the absence of symptom and "3" represents the severe symptom. The resolution of influenza-related symptoms is defined as the beginning of the 24-hour period that 7 influenza symptoms (cough, sore throat, headache, nasal congestion, feeling feverish, body aches and pains, fatigue) are at most mild or at least back to previous level of symptom severity in case the participant reported the symptom as pre-existing.
Measured: Up to Day 28
Secondary outcomes (8)
Number of Participants Hospitalized After Treatment Initiation
The number of participants hospitalized after treatment initiation were reported.
Measured: Up to Day 28
Viral Load Over Time
Viral load over time was measured by quantitative real time polymerase chain reaction (qRT-PCR) and viral culture in the mid-turbinate (MT) nasal swabs and endotracheal samples.
Measured: Baseline, Day 3, 6, 10, 14
Number of Participants With Emergence of Viral Resistance to Pimodivir
Emergence of viral resistance to pimodivir was detected by genotyping and/or phenotyping. Nasal MT swabs and endotracheal samples were used for sequence analysis of the polymerase basic protein (PB)2 region of the influenza polymerase gene, and of neuraminidase (NA) genes for participants using an NA inhibitor (NAI) as part of their Standard of Care (SOC).
Measured: Up to Day 28
Plasma Concentration of Pimodivir
Plasma concentration of Pimodivir was reported.
Measured: Day 3, 6, 7
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Measured: Up to Day 28
Number of Participants With Clinically Significant Changes in Laboratory Tests
Number of participants with clinically significant changes in laboratory tests were reported. Blood samples for hematology, serum chemistry, and urinalysis was collected at predefined time points for clinical laboratory testing.
Measured: Up to Day 28
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG)
Number of participants with clinically significant changes in Electrocardiogram (ECG) were reported.
Measured: Up to Day 28
Number of Participants With Clinically Significant Changes in Vital Signs
Number of participants with clinically significant changes in vital signs (temperature, pulse rate, respiratory rate and blood pressure) were reported.
Measured: Up to Day 28
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Dec 2017
- Study start21 Jan 2018
- Primary completion28 May 2020
- Study completion24 Aug 2020
Why it stopped: Based on interim Analysis outcome being futile for FLZ3001; decision was taken to stop (early terminate) both FLZ3001/3002. There was no safety concern.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Influenza AStudies of the same condition, open and under way.
- More trials run by Janssen Research & Development, LLCThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 553 participants (actual)
Sponsor and investigators
- Lead sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Janssen Research & Development, LLC Clinical Trial, Study director, Janssen Research & Development, LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03381196
- Sponsor's protocol ID
- CR108400
- Other IDs
- 2017-002217-59, 63623872FLZ3002, 2017
- Status last verified
- Jan 2025
- First submitted
- 18 Dec 2017
- Last updated
- 4 Feb 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Expanded access
- Available
Publications
Leopold L, Vingerhoets J, Deleu S, Nalpas C, Weber K, van Dromme I, Lowson D, Michiels B, van Duijnhoven W. Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection. J Infect Dis. 2025 Feb 4;231(1):e132-e143. doi: 10.1093/infdis/jiae408.
PubMed 39172627
Study at a glance
From the registry record, last updated by the sponsor on 4 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized Subjects With Influenza A Infection Who Are at Risk of Developing Complications
- ClinicalTrials.gov ID
- NCT03381196
- Acronym / sponsor ID
- CR108400
- Conditions
- Influenza A
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Based on interim Analysis outcome being futile for FLZ3001; decision was taken to stop (early terminate) both FLZ3001/3002. There was no safety concern.
- Enrolment
- 553 participants (actual)
- Lead sponsor
- Janssen Research & Development, LLCIndustry (pharma, biotech, devices)
- Study start
- 21 Jan 2018 (actual)
- Primary completion
- 28 May 2020 (actual)
- Study completion
- 24 Aug 2020 (actual)
- First posted
- 21 Dec 2017 (actual)
- Results
- Posted 24 May 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the clinical and virologic benefit of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment.
Detailed description
This double-blind (neither researchers nor participants know what treatment participant is receiving) study will evaluate efficacy/safety of pimodivir in combination with SOC treatment versus placebo in combination with SOC treatment in adolescent (13 to 17 years), adult (18 to 65 years), and elderly (greater than [>] 65 but less than or equal to [<=] 85 years) non-hospitalized participants with influenza A infection who are at risk of developing complications. The study will be conducted in 3 phases: screening phase, double-blind treatment period (5 days), a post treatment follow-up period (23 days). Study evaluations include efficacy, clinical and virological outcomes, pharmacokinetics (PK), PK/pharmacodynamics, biomarkers, safety and tolerability. The duration of participation in the study for each participant is 28 days.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Treatment Arm 1 (pimodivir + SOC treatment) | Experimental | Drug: Pimodivir 600 mg, Other: SOC TreatmentParticipants will receive pimodivir 600 milligram (mg), orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6) along with Standard-of-Care (SOC) treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected adverse event (AE). |
| Treatment Arm 2 (placebo + SOC treatment) | Placebo comparator | Drug: Placebo, Other: SOC TreatmentParticipants will receive placebo matching to pimodivir orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until the morning of Day 6) along with SOC treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE. |
Who may qualify
- Ages
- 13 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- Present to the clinic with symptoms suggestive of a diagnosis of acute influenza and have at least 1 respiratory symptom and at least 1 systemic symptom, both scored as at least "moderate" if the symptom did not pre-exist before influenza onset, or scored worse than usual if the symptom pre-existed as determined by subject's ratings on Module 1 of the Flu-iiQ and the Pre-existing Symptom Questionnaire in the ePRO device. Symptoms must include the following by category: a) Respiratory symptoms: cough, sore throat, nasal congestion b) Systemic symptoms: headache, body aches or pain, feverishness, fatigue
- Tested positive for influenza A infection after the onset of symptoms, using a rapid influenza diagnostic test (RIDT) or, if available, a polymerase chain reaction (PCR)-based or other rapid molecular diagnostic assay
- Not be in need of hospitalized medical care at screening. Emergency room or hospital observation status for an anticipated duration of less than (<)24 hours is not considered hospitalization as long as a determination of the need for hospitalization has not been made
- Enrollment and initiation of study drug treatment less than or equal to (<=)72 hours after onset of influenza symptoms
- Participants 13 to 65 years of age, inclusive must also have at least 1 of the following: a) Cardiovascular or cerebrovascular disease (including congenital heart disease, chronic heart failure, coronary artery disease, or stroke; excluding isolated hypertension); b) Chronic lung disease (for example, asthma, chronic obstructive lung disease [COPD] or cystic fibrosis); c) Weakened immune system due to disease or medication (for example, participants with human immunodeficiency virus [HIV], cancer, or chronic liver or kidney disease [presence of kidney damage for >3 months, defined by structural or functional abnormalities of the kidney, with or without decreased GFR manifested by: pathological abnormalities; OR markers of kidney damage, including abnormalities in the composition of the blood or urine or abnormalities in imaging tests], or participants taking chronic systemic steroids)
Key exclusion criteria (5 listed)
- Received more than (>)1 dose of influenza antiviral medication (for example, oseltamivir [OST] or zanamivir), or any dose of ribavirin within 2 weeks, prior to first study drug intake, or received intravenous (IV) peramivir >1 day prior to screening
- Unstable angina pectoris or myocardial infarction within 30 days prior to screening (inclusive)
- Presence of clinically significant heart arrhythmias, uncontrolled, unstable atrial arrhythmia, or sustained ventricular arrhythmia, or risk factors for Torsade de Pointes syndrome
- Known severe hepatic impairment (Child Pugh C cirrhosis) or chronic hepatitis C infection undergoing hepatitis C antiviral therapy
- Severely immunocompromised in the opinion of the investigator (for example, known cluster of differentiation 4 plus [CD4+] count <200 cells per cubic millimeter [cells/mm^3], absolute neutrophil count <750/mm^3, first course of chemotherapy completed within 2 weeks prior to screening, history of stem cell transplant within 1 year prior to screening, history of a lung transplant)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pimodivir 600 mgAlso: JNJ-63623872Participants will receive pimodivir 600 mg, orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6). | Drug | Treatment Arm 1 (pimodivir + SOC treatment) |
| PlaceboParticipants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until the morning of Day 6). | Drug | Treatment Arm 2 (placebo + SOC treatment) |
| SOC TreatmentParticipants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). | Other | Treatment Arm 1 (pimodivir + SOC treatment), Treatment Arm 2 (placebo + SOC treatment) |
Primary outcome
Time to Resolution of 7 Primary Influenza-related Symptoms as Assessed by the Patient-Reported Outcome (PRO) Measure Flu-Intensity and Impact Questionnaire (Flu-iiQ)
Time frame: Up to Day 28
The Flu-iiQ is a PRO that measures influenza symptom intensity (none, mild, moderate, or severe) on a 4 point Likert response rating scale ranging from 0 to 3, where "0" represents the absence of symptom and "3" represents the severe symptom. The resolution of influenza-related symptoms is defined as the beginning of the 24-hour period that 7 influenza symptoms (cough, sore throat, headache, nasal congestion, feeling feverish, body aches and pains, fatigue) are at most mild or at least back to previous level of symptom severity in case the participant reported the symptom as pre-existing.
8 secondary outcomes
Number of Participants Hospitalized After Treatment Initiation
Time frame: Up to Day 28
Viral Load Over Time
Time frame: Baseline, Day 3, 6, 10, 14
Number of Participants With Emergence of Viral Resistance to Pimodivir
Time frame: Up to Day 28
Plasma Concentration of Pimodivir
Time frame: Day 3, 6, 7
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Time frame: Up to Day 28
Number of Participants With Clinically Significant Changes in Laboratory Tests
Time frame: Up to Day 28
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG)
Time frame: Up to Day 28
Number of Participants With Clinically Significant Changes in Vital Signs
Time frame: Up to Day 28
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Feb 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 39172627Leopold L, Vingerhoets J, Deleu S, Nalpas C, Weber K, van Dromme I, Lowson D, Michiels B, van Duijnhoven W. Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection. J Infect Dis. 2025 Feb 4;231(1):e132-e143. doi: 10.1093/infdis/jiae408.
Related trials for Influenza A
Not yet recruitingPhase 1
Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates
Influenza
RecruitingPhase 1
pH1N1 Blinded Challenge Study
Influenza
RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
Influenza
RecruitingPhase 1
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children
Seasonal Influenza
RecruitingPhase 1
A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)
Healthy Participants
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Janssen Research & Development, LLC Clinical Trial study director
Janssen Research & Development, LLC
427 sites in 38 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Pimodivir 600 mg and SOC Treatment in people with Influenza A, run by Janssen Research & Development, LLC at 427 sites in 38 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 4 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 427 sites in United States, South Africa, Hungary, Argentina, India and 33 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 24 May 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to Resolution of 7 Primary Influenza-related Symptoms as Assessed by the Patient-Reported Outcome (PRO) Measure Flu-Intensity and Impact Questionnaire (Flu-iiQ) (time frame: Up to Day 28). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03381196, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2025.